136 related articles for article (PubMed ID: 18220942)
1. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
Chan DC; Watts GF
Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
Watts GF; Ooi EM; Chan DC
Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
Chan DC; Barrett PH; Watts GF
Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
[TBL] [Abstract][Full Text] [Related]
6. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
Chan DC; Barrett PH; Watts GF
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes.
Watts GF; Chan DC
Atheroscler Suppl; 2010 Jun; 11(1):61-4. PubMed ID: 20452838
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
9. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
Watts GF; Chan DC; Ooi EM; Nestel PJ; Beilin LJ; Barrett PH
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):877-82. PubMed ID: 16922825
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
[TBL] [Abstract][Full Text] [Related]
11. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
[TBL] [Abstract][Full Text] [Related]
12. The compositional abnormalities of lipoproteins in diabetic renal failure.
Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
[TBL] [Abstract][Full Text] [Related]
13. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
[TBL] [Abstract][Full Text] [Related]
14. Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.
Ying Q; Chan DC; Barrett PHR; Watts GF
Metabolism; 2021 Nov; 124():154887. PubMed ID: 34508741
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Staels B; Dallongeville J; Auwerx J; Schoonjans K; Leitersdorf E; Fruchart JC
Circulation; 1998 Nov; 98(19):2088-93. PubMed ID: 9808609
[TBL] [Abstract][Full Text] [Related]
16. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
[TBL] [Abstract][Full Text] [Related]
17. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
18. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
19. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders.
Chan DC; Barrett PH; Watts GF
Curr Opin Lipidol; 2006 Feb; 17(1):28-36. PubMed ID: 16407713
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
